Video

Dr Peter Hillmen Outlines Zanubrutinib as a New Option to Treat in R/R CLL

Ibrutinib is currently a standard of care in relapsed/refractory chronic lymphocytic leukemia, but zanubrutinib is an effective second-line and second-generation option, said Peter Hillmen, PhD, MB ChB, professor at the University of Leeds.

Ibrutinib is currently a standard of care in relapsed/refractory chronic lymphocytic leukemia, but zanubrutinib is an effective second-line and second-generation option, said Peter Hillmen, PhD, MB ChB, professor at the University of Leeds and honorary consultant hematologist at Leeds Teaching Hospitals NHS Trust.

Transcript

Ibrutinib is a standard of care in chronic lymphocytic leukemia. How can zanubrutinib differentiate itself as a treatment of choice?

So, I think ibrutinib is one of the standards of care, for sure, and we have a lot of mature data for ibrutinib in relapsed disease. So, it continues to be important treatment. I think we need more data and larger trials of safety for ibrutinib going forward, to look at those rare complications we see with BTK [Bruton tyrosine kinase] inhibition.

I think the zanubrutinib is an effective second-line, also second-generation, BTK inhibitor, and where available, you know, may say displace ibrutinib in some patient groups, I think. It's given twice a day, which is slightly less convenient, but most patients are fine. It can cause a little bit more neutropenia but doesn't seem to cause more infection. So, it's been, it's very well tolerated. I think it gives us more options with the number of BTK inhibitors is coming through.

Related Videos
Pierluigi Porcu, MD
Benjamin Chen, MD, PhD
4 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
4 experts are featured in this series.
Kimberly Westrich, MA, chief strategy officer, NPC
Erin Weber, MS
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo